The Danish pharmaceutical giant Novo Nordisk has started selling its weight loss drug Wegovy on the Chinese market, the company reports to the news agency AFP. Wegovy was approved for use in China last summer and now the first patient has been prescribed the medication.
Originally a diabetes medication, Wegovy, along with Ozempic, has become a gigantic sales success as the preparations have proven to be effective in weight loss as well. The success has in turn made Novo Nordisk one of the world's highest-valued companies.
The Chinese market is simultaneously considered extremely lucrative since overweight has become a major social problem. More than half of all adults in China are estimated to suffer from overweight, according to a study published last year.
